Repligen stock price target reaffirmed at $225 by UBS on growth outlook

UBS has reaffirmed its Buy rating and $225 price target for Repligen (NASDAQ: RGEN), citing incremental optimism across several growth areas including MFN and equipment tailwinds, China growth, the BioLife deal, new modalities like mRNA, and potential financial upside. The bioprocessing company's stock has surged 76% in the past six months and its recent Q2 2026 earnings surpassed expectations, leading to a raised full-year outlook. Despite the positive outlook from UBS, InvestingPro data sugges